Article Sidebar
Views pdf: 92
INCIDENCE AND CLINICAL-PARACLINICAL CHARACTERISTICS OF HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY PES PATHOGENS
Main Article Content
Abstract
Objectives: To describe the incidence and the clinical and paraclinical characteristics of patients with community-acquired pneumonia caused by PES bacteria at Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital. Methods: A cross-sectional descriptive study was conducted on 200 cases of community-acquired pneumonia with positive bacterial culture from lower respiratory tract specimens between August 2022 and May 2024. Results: The incidence of community-acquired pneumonia caused by PES was 26%. The typical clinical characteristics of patients with PES-associated pneumonia included age > 65 years (78.8%); female gender (71.2%); respiratory failure (69.2%); Pneumonia Severity Index (PSI) scores of IV–V (73.1%); CURB-65 scores ≥ 3 (69.2%); multi-lobar lung lesions on chest X-ray (90.4%). Conclusions: The incidence of community-acquired pneumonia caused by PES bacteria is increasing. This condition presents several unique clinical characteristics that are critical for early diagnosis.
Article Details
Keywords
Community-acquired pneumonia, PES, clinical characteristics, paraclinical characteristics.
References
2. Cillóniz C, Dominedò C, Torres A. Multidrug-Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. Crit Care. 2019 Mar 9;23(1):79. doi: 10.1186/s13054-019-2371-3.
3. Prina E, Ranzani OT, Polverino E, et al. A. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015 Feb;12 (2):153-60. doi: 10.1513/ AnnalsATS.201407-305OC.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2(Suppl 2): S27-72. doi: 10.1086/511159.
5. Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. European Respiratory Journal. 2018, 52: 1701190; DOI: 10.1183/13993003.01190-2017
6. Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, Arita M. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: Evaluation of PES pathogens. J Infect Chemother. 2017, 23(1):23-28. doi: 10.1016/j.jiac.2016.09.002. Epub 2016 Oct 8. PMID: 27729192.
7. Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis. 2012; 54(2):193-8. doi: 10.1093/cid/cir813.
8. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012; 54(4):470-8. doi: 10.1093/cid/cir840.
9. Cavallazzi R, Furmanek S, Arnold FW, et al. The burden of community-acquired pneumonia requiring admission to ICU in the United States. Chest 2020; 158: 1008–1016. doi:10.1016/j.chest.2020.03.051.
10. Leem AY, Jung WJ, Kang YA, et al. Comparison of methicillin-resistant Staphylococcus aureus community-acquired and healthcare-associated pneumonia. Yonsei Med J. 2014; 55(4):967-74. doi: 10.3349/ ymj.2014.55.4.967.